| |
| |
|
| Insider
Information: |
Leonhardt Harry J |
| Relationship: |
|
| City: |
La Jolla |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
329,950 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$3,017,190 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
329,950 |
|
|
| Total
Value |
$3,017,190 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Senomyx Inc |
SNMX |
SVP, Gen.Counsel & Cor... |
2007-09-04 |
48,937 |
|
0 |
Premium* |
|
|
Amylin Pharmaceuticals Inc |
AMLN |
SVP, Legal, Compl & Co... |
2012-08-08 |
0 |
2012-08-08 |
0 |
Premium* |
|
|
Halozyme Therapeutics Inc |
HALO |
SVP, GC |
2019-04-13 |
66,373 |
2016-04-13 |
0 |
Premium* |
|
|
Poseida Therapeutics, Inc. |
PSTX |
|
2024-03-01 |
214,640 |
2022-03-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PSTX |
Poseida Therapeutics, Inc... |
GC & Chief Compliance Officer |
• – – |
2024-03-01 |
4 |
D |
$4.13 |
$67,344 |
D/D |
(16,306) |
214,640 |
0 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
GC & Chief Compliance Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
80,743 |
230,946 |
0 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
GC & Chief Compliance Officer |
• – – |
2023-03-01 |
4 |
D |
$5.35 |
$23,128 |
D/D |
(4,323) |
144,203 |
0 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
GC & Chief Compliance Officer |
• – – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
92,772 |
148,526 |
0 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
GC & Chief Compliance Officer |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-04-13 |
4 |
D |
$16.54 |
$39,316 |
D/D |
(2,377) |
66,373 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-04-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,875 |
68,750 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,392 |
65,814 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-02-22 |
4 |
D |
$16.81 |
$66,215 |
D/D |
(3,939) |
61,875 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-02-14 |
4 |
D |
$16.54 |
$44,658 |
D/D |
(2,700) |
54,422 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,809 |
57,122 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-02-03 |
4 |
D |
$16.12 |
$91,207 |
D/D |
(5,658) |
49,313 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC |
• – – |
2019-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,413 |
54,971 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC and CCO |
• – – |
2018-04-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,875 |
41,935 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC and CCO |
• – – |
2018-04-13 |
4 |
D |
$19.37 |
$46,042 |
D/D |
(2,377) |
39,558 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC and CCO |
• – – |
2018-02-22 |
4 |
D |
$19.28 |
$75,944 |
D/D |
(3,939) |
35,060 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC and CCO |
• – – |
2018-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,392 |
38,999 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC and CCO |
• – – |
2018-02-03 |
4 |
D |
$18.37 |
$102,964 |
D/D |
(5,605) |
27,607 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC and CCO |
• – – |
2018-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,413 |
33,212 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC and CCO |
• – – |
2017-04-13 |
4 |
D |
$12.81 |
$33,088 |
D/D |
(2,583) |
17,799 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC and CCO |
• – – |
2017-04-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,875 |
20,382 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC and CCO |
• – – |
2017-02-03 |
4 |
D |
$12.26 |
$75,987 |
D/D |
(6,198) |
13,507 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC and CCO |
• – – |
2017-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,413 |
19,705 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC and CCO |
• – – |
2016-04-13 |
4 |
D |
$11.76 |
$30,376 |
D/D |
(2,583) |
4,292 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, GC and CCO |
• – – |
2016-04-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,875 |
6,875 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
